The focus during 2018 has been on making the two clinical assets PXL01 and LL-37 ready to enter the next clinical development phase. During the autumn, the first goal was achieved, and the Phase 2b HEAL LL-37 trial started. However, the most important study is yet to be initiated, the Phase 3 clinical trial with PXL01, which we expect will begin early in 2019.